Celgene have made a $50 million payment to Juno to take up an option on their CAR-T effort. The deal will provide development and commercialization rights for the CD19 program in Europe and other territories outside China and North America.
Celgene are already at the forefront of CAR T therapies, having previously struck a $1 billion deal with Juno, giving them a leading role.
Juno currently has three therapies in development that target the CD19 receptor. JCAR015 is currently undergoing a Phase II trial for adults with relapsed/refractory acute lymphoblastic leukemia. JCAR017 is currently in two Phase I trials, one in pediatric patients with acute lymphoblastic leukaemia (ALL) and another in patients with non-Hodgkin lymphoma (NHL). JCAR014 is in a Phase I trial in adult ALL, NHL, and chronic lymphocytic leukemia. In addition, JCAR014 is also part of a combination trial with durvalumab, AstraZeneca’s PD-L1 immune checkpoint inhibitor.
“Celgene’s development and commercial expertise, particularly in hematologic malignancies, make them our ideal partner and will accelerate our global development capabilities for patients with ALL, CLL, and NHL. The long-term collaboration with Celgene is an important component of our plan to develop our engineered T cell platform rapidly and effectively for the benefit of patients around the world, and we are encouraged by the progress we are making together,” said Hans Bishop, Juno’s President and CEO.
Source: Celgene and Juno Announce Celgene Exercised Option to Develop and Commercialize CD19-directed Product Candidates; Press Release